![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
|Articles|March 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 3
- Volume 4
- Issue 3
Medicare Physician Fees Set for 1995
WASHINGTON--Health and Human Services Secretary Donna Shalala has announced that Medicare physician fees will be increased in 1995--by 7.9% for primary services, 12.2% for surgical services, and 5.2% for other services. Payments for
Advertisement
WASHINGTON--Health and Human Services Secretary Donna Shalalahas announced that Medicare physician fees will be increased in1995--by 7.9% for primary services, 12.2% for surgical services,and 5.2% for other services. Payments for physician services incalendar year 1995 are expected to be $2.2 billion higher thanin 1994
Articles in this issue
over 31 years ago
Selecting a Support Group for Patients With Prostate Carcinomaover 31 years ago
Antman Provides Outlook on Use of High-Dose Chemoover 31 years ago
Radiofrequency Ablation of Brain Tumors New Optionover 31 years ago
Oncologist Enthusiastic About Capitated Planover 31 years ago
Varmins Chooses New Director for NIH Office of Alternative Medicineover 31 years ago
'Visible Man' Hits the Internet, Radiologists Get the First Lookover 31 years ago
Ultrafast Full-Body MRI Eases Procedure in Claustrophobics, KidsAdvertisement
Related to this article
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.
T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
4
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
5